Information, not a decision

Ovarian cancer: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 15 Nov 2026

Open trials (890)

NCT06843447	Phase 1/2	A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).	Recruiting
NCT07488676	Phase 1/2	A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors	Recruiting
NCT07360314	Phase 1	Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors	Recruiting
NCT06964009	Phase 1	DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer	Recruiting
NCT07923214	Phase 1	A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors	Recruiting
NCT07791732	Phase 3	A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)	Not yet recruiting
NCT04585958	Phase 1	Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer	Recruiting
NCT07664735	Phase 1	A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.	Recruiting
NCT07931313	Phase 2/3	PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer	Not yet recruiting
NCT05950464	Phase 1	Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer	Recruiting
NCT01174121	Phase 2	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer	Recruiting
NCT04847063	Phase 1	Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies	Recruiting

878 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

NCT01167712

14 Sept 2026

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 15 Nov 2026

https://frontlightresearch.com/en/doctor/ovarian-cancer/tumor-board